Formulating a national position statement and guide on modern theranostics in the Philippines

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Therapy
• Oncology

Background:

• Advanced theranostics, including Ga-68 and Lu-177 PSMA and DOTATATE, were introduced in the Philippines in 2018.
• Initial adoption faced challenges, including limited growth and distribution of radiopharmaceuticals.
• International guidelines from major nuclear medicine societies emerged due to the rapid expansion of theranostics.

Purpose of the Study:

• To describe the implementation of theranostic position statements in the Philippines.
• To adapt international standards for local feasibility and future development.
• To ensure patient safety and establish practice standards for theranostics.

Main Methods:

• Review and adaptation of international position statements from organizations like EANM, SNMMI, and IAEA.
• Modification of guidelines for local applicability within the Philippine Society of Nuclear Medicine.
• Involvement of diverse representatives and mobilization of groups for implementation.

Main Results:

• Successful adoption and modification of international theranostic guidelines by the Philippine Society of Nuclear Medicine in late 2022.
• Implementation involved collaborative efforts and adaptation to local context.
• Inclusion of a liability clause to promote professional conduct.

Conclusions:

• The Philippines has established a framework for safe and standardized theranostic practice.
• Adaptation of international guidelines facilitates the integration of advanced nuclear medicine treatments.
• Collaborative efforts and regulatory measures are crucial for the successful implementation of novel medical technologies.